9 Results for "

anti-angiogenesis agent

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "anti-angiogenesis agent" in MCE Product Catalog:

Cat. No.: HY-N7449
CAS No.: 3947-65-7
Neamine, a degradation product of Neomycin, is a broad-spectrum aminoglycoside antibiotic. Neamine is an anti-angiogenesis agent targeting angiogenin. Neamine has potent antibacterial, antitumor and neuroprotective activities .
loading...
    loading...
Cat. No.: HY-115349
CAS No.: 15446-43-2
Purity:  99.92%
Target:  

Antibiotic Bacterial

Research Areas:  

Infection Neurological Disease Cancer

Neamine tetrahydrochloride, a degradation product of Neomycin, is a broad-spectrum aminoglycoside antibiotic. Neamine tetrahydrochloride is an anti-angiogenesis agent targeting angiogenin. Neamine tetrahydrochloride has potent antibacterial, antitumor and neuroprotective activities .
loading...
    loading...
Cat. No.: HY-149920
CAS No.: 2857070-72-3
Target:  

Microtubule/Tubulin

Research Areas:  

Cancer

Anticancer agent 98 (compound 12k) is a microtubule/tubulin-polymerization inhibitor (Kd=16.9 μM). Anticancer agent 98 exerts antiproliferative potency against tumor cells, exhibits anti-angiogenesis effect in vitro. Anticancer agent 98 exhibits good human and mouse liver microsomes stability with both t1/2>300 min .
loading...
    loading...
Cat. No.: HY-101990
CAS No.: 1031206-36-6
Purity:  99.81%
Target:  

VEGFR

Research Areas:  

Others

IMS2186 is an anti-choroidal neovascularization (CNV) agent that inhibits angiogenesis upstream of VEGF. IMS2186 can arrest cancer cell cycle in G2/M phase, thus exerting anti-proliferation and anti-angiogenesis effects. IMS2186 has no intraocular toxicity and reduces the amount of eye leakage and diseased cells .
loading...
    loading...
Cat. No.: HY-N7449R
CAS No.: 3947-65-7
Neamine, a degradation product of Neomycin, is a broad-spectrum aminoglycoside antibiotic. Neamine is an anti-angiogenesis agent targeting angiogenin. Neamine has potent antibacterial, antitumor and neuroprotective activities .
loading...
    loading...
Cat. No.: HY-148291
CAS No.: 944265-88-7
Research Areas:  

Cancer

BrP-LPA sodium is a pan-opposite agent for lysophosphatidic acid (LPA). It has antagonistic activity against LPA1 (IC50 = 4520 nM), LPA2 (IC50 = 468 nM), LPA3, and LPA4. BrP-LPA sodium also has partial agonistic activity for LPA5, with its EC50 being 1282 nM. BrP-LPA sodium has ATX inhibitory activity. BrP-LPA sodium effectively inhibits the migration and invasion of breast cancer cells. BrP-LPA sodium achieves tumor regression and anti-angiogenesis in mice breast cancer xenograft model. BrP-LPA sodium can be used for the study of breast cancer .
loading...
    loading...
Cat. No.: HY-144331
CAS No.: 2763621-91-4
Research Areas:  

Cancer

Antitumor agent-42 (Compound 15h) is a bifunctional agent exhibiting both tubulin polymerized inhibition and NO-releasing activities, resulting in potent anti-angiogenesis, colony formation inhibition, cell cycle arrest and apoptosis induction effects .
loading...
    loading...
Cat. No.: HY-183377
CAS No.: 1260071-76-8
DMBT is an orally effective anti-tumor metastasis and anti-angiogenesis agent. DMBT downregulates key molecules such as EGFR/p-Akt/HIF-1α/VEGF/MMP-9, inhibits the HIF-1α/VE-cadherin (cadherin)/MMPs and Nrf2/HO-1 signaling pathways, and reduces hypoxia-induced ROS levels as well as the secretion and activity of MMP-9. DMBT inhibits hypoxia-induced vasculogenic mimicry, cancer cell migration, invasion and metastasis, and exhibits no obvious cytotoxicity to normal cells. DMBT reduces the area of laser-induced choroidal neovascularization lesions. DMBT can be used in studies related to breast cancer, melanoma and macular degeneration .
loading...
    loading...
Cat. No.: HY-116721
CAS No.: 638216-89-4
Target:  

VEGFR

Research Areas:  

Cardiovascular Disease

AG-28262 is a VEGFR inhibitor. AG-28262 has anti-angiogenesis activity .
loading...
    loading...